Journal article
Spread of artemisinin resistance in Plasmodium falciparum malaria
EA Ashley, M Dhorda, RM Fairhurst, C Amaratunga, P Lim, S Suon, S Sreng, JM Anderson, S Mao, B Sam, C Sopha, CM Chuor, C Nguon, S Sovannaroth, S Pukrittayakamee, P Jittamala, K Chotivanich, K Chutasmit, C Suchatsoonthorn, R Runcharoen Show all
New England Journal of Medicine | Published : 2014
Abstract
BACKGROUND: Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now poses a threat to the control and elimination of malaria. Mapping the geographic extent of resistance is essential for planning containment and elimination strategies. METHODS: Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries (7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, for 3 days, followed by a standard 3-day course of artemisinin-based combination therapy. P..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
Supported by grants from the U.K. Department for International Development, the Worldwide Antimalarial Resistance Network, the Intramural Research Program of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, and the Bill and Melinda Gates Foundation. The Mahidol-University Oxford Tropical Medicine Research Programme is funded by the Wellcome Trust of Great Britain.